Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response and the duration of it in patients
affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment
that will be treated with crizotinib.